[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wuxi Hisky Medical Technology Co Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100577779",false,"NCT06802731","LivQ-box® Parameters in the Diagnosis of Liver Inflammation","A Multicenter Study on the Application of LivQ-box® Parameters in the Diagnosis of Liver Inflammation in Patients with Non-alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases;\n* Age over 18 years old, gender not limited;\n* Not combined with liver diseases (such as viral hepatitis, drug-induced liver injury, autoimmune liver disease);\n* Perform iLivTouch examination within ± 14 days of liver pathology examination;\n* No history of excessive alcohol consumption (converted to ethanol:\\\u003C140g\u002Fweek for males,\\\u003C70g\u002Fweek for females);","ALL","18 Years",{"count":18,"type":19},365,"ESTIMATED","OBSERVATIONAL","To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.",[23,24],"Liver Inflammation","Fatty Liver Disease","RECRUITING","2025-01-24",{"date":28,"type":29},"2025-01-31","ACTUAL",{"date":31,"type":29},"2024-01-01",{"date":33,"type":19},"2025-06-30",{"name":35,"class":36},"Wuxi Hisky Medical Technology Co Ltd","INDUSTRY",1,{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":46,"conditions":47,"keywords":50,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":37},"100485179","NCT05597709","Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China","Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes\n* UAP were measured based on iLivTouch\n* Willing to attend this study and able to provide the written informed consent.\n\nExclusion Criteria:\n\n* Other types of diabetes\n* Patients unable to receive regular follow-up",{"count":45,"type":19},2900,"In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.",[48,49],"Type 2 Diabetes Mellitus in Remission","Metabolic Associated Fatty Liver Disease",[51,52,53],"Type 2 diabetes mellitus","Metabolic associated fatty liver disease","ultrasound attenuation parameter","2022-10-24",{"date":56,"type":29},"2022-10-28",{"date":58,"type":29},"2022-07-01",{"date":60,"type":19},"2027-06-01",{"name":35,"class":36},""]